News Press release

SeqOne Genomics selected as genomic analysis solution for CELIA (Comprehensive Genomic profiling impact) project, in collaboration with Illumina

4 February 2022

This post is also available in French

The project aims to compare the clinical utility of broad-spectrum genomic profiling in the treatment of late-stage cancer patients with more traditional approaches that analyze a limited set of genes and thus influence the precision medicine strategy of the French national health system

Montpellier February 4, 2022, SeqOne Genomics, developer of next generation genomic analysis solutions, announced that it has been selected to analyze Illumina TruSight™ Oncology 500 genomic data that will be generated over the course of the CELIA project. The data will be generated by three medical establishments: the Centre Jean Perrin, part of the Clermont-Ferrand hospital, the university teaching hospital of Bordeaux and the Toulouse oncology center (Oncopôle Toulouse).

SeqOne will supply its genomic analysis platform to assist biologists in interpreting the data and generating a full clinical report necessary for the treatment of patients or their inclusion in relevant clinical trials. Illumina will support the project by supplying reagents necessary for the genetic profiling as well as statistical analysis of the results of the project.

“We are pleased to participate in this important project by contributing our expertise in analyzing genomic data.  We view our involvement as recognition of our expertise in this domain. The project also aligns perfectly with our ambition to make personalized medicine accessible to all.” said Nicolas Philippe Ph.D., Co-founder and CEO of SeqOne Genomics.

Pr. Pascal. Pujol, President of the la SFMPP (French Society of Predictive and Personalized Medicine) stated, “I am happy to see such a project being launched in France.  It will further demonstrate the relevance of complete genomic profiling and hence accelerate the adoption of precision medicine for patients suffering from cancer.  SeqOne is the ideal partner for this project as their solution addresses the needs of biologists and oncologists while providing clear and comprehensive clinical reports, all essential requirements in this project that seeks to transform the approach to the treatment of late-stage cancer patients. 

About SeqOne Genomics

SeqOne Genomics offers high performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning  coupled with the company’s proprietary GeniOS™ genomics operating system to dramatically reduce turnaround times and costs while delivering a comprehensive and actionable insights for personalised medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize.Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes and Software Club.


Web: https://seqone.com

SeqOne Genomics media relations

Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59

Juliette Milleret – jmilleret@newcap.fr /+33 (6) 98 50 21 93

  

Comments

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Need help improving your genomic analysis process ?
We'd love to help !